stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
12.30 | 16.24 | 22.61 | 19.85 |
+8 more quarters Free account |
Net Debt/EBITDA |
36.12 | 7.41 | 9.16 | 9.32 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.07) | 0.74 | 0.87 | 0.77 | |
Capex/Depreciation |
0.01 | 0.15 | 0.61 | 0.08 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.72) | (0.39) | (0.40) | (0.38) | |
Cash per Share |
16.02 | 4.28 | 4.66 | 5.15 | |
Shareholders Equity per Share |
15.00 | 4.16 | 4.60 | 5.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.00 | 4.16 | 4.60 | 5.07 | |
Free Cash Flow |
(78.31) | (42.50) | (42.80) | (38.66) | |
Working Capital |
1,628.36 | 442.48 | 487.25 | 516.02 | |
Capital Expenditures |
(0.02) | (0.03) | (0.26) | (0.07) | |
Net Current Asset Value |
1,625.12 | 439.91 | 484.47 | 513.04 | |
| Other line items | |||||
Quick Ratio |
12.10 | 15.86 | 22.16 | 19.37 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.72) | (0.39) | (0.40) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
7.90 | 6.49 | 8.04 | 5.79 | |
Average Assets |
1,181.74 | 546.51 | 486.46 | 519.71 | |
Average Common Equity |
1,095.66 | 518.57 | 461.46 | 490.74 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026